HispanicBusiness

The EPIC V-Series features a 940nm wavelength with 10 watts of power as well as an intuitive procedure-based graphical touchscreen. It also uses BIOLASE's proprietary ComfortPulse™ control technology that minimizes tissue damage and avoids pain-inducing heat buildup at the surgical site.

"The EPIC V-Series is more competitively priced than other high-powered lasers in the veterinary market and features a revolutionary and intuitive applications-based user interface. The high-resolution touch screen is pre-programmed with several of the most commonly performed veterinary soft tissue procedures, including pain therapy, which is a highly popular treatment for pets. It is also the only laser in the market with our patented EZ Tips technology for dental and surgical procedures," Pignatelli concluded.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate approximately 290 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 22,000 lasers. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolaseinc, Twitter at twitter.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results, expected outcomes or approvals, or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's product introductions, strategic initiatives, and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current perspective of existing trends and information and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors affecting BIOLASE's business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.



Add to Digg Bookmark with del.icio.us Add to Newsvine



For further information, please contact:
Lisa Wilson
In-Site Communications, Inc.
212-759-3929